A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients

Clinical Infectious Diseases

Volumn 30, Issue 2, 2000, Pages 300-305

  Nucci, Marcio ^a   Biasoli, Irene ^a   Akiti, Tiyomi ^a   Silveira, Fernanda ^a   Solza, Cristiana ^b   Barreiros, Gloria ^a   Spector, Nelson ^a   Derossi, Andrea ^b   Pulcheri, Wolmar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FUNGEMIA; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034099841     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313654     Document Type: Article

References (22)

1. 1. Bodey GP. Infection in cancer patients: a continuing association. Am J Med 1986; 81:11-26.
2. 2. Bow EJ. Invasive fungal infections in patients receiving intensive cytotoxic therapy for cancer. Br J Haematol 1998; 101(Suppl 1):1-4.
3. 3. Walsh TJ, Lee JW. Prevention of invasive fungal infections in patients with neoplastic diseases. Clin Infect Dis 1993; 17(Suppl 2):S468-80.
4. 4. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
5. 5. Slavin M, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
6. 6. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118:495-503.
7. 7. Rilley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509-14.
8. 8. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165:891-7.
9. 9. Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy: a double-blind, placebo controlled study. Leuk Lymphoma 1993; 11:353-8.
10. 10. Van Peer A, Woestenborghs R, Van de Velde V, Heykants J, Van Rooy P, Cauwenburgh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989; 36:423-6.
11. 11. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
12. 12. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172:1035-41.
13. 13. Nucci M, Akiti T, Silveira F, et al. Fungemia due to Exophiala jeanselmei: report of 23 cases [abstract J141]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:491.
14. 14. Menichetti F, Del Favero A, Martino P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120:913-8.
15. 15. Uzum O, Anaissie EJ. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 1995; 86:2063-72.
16. 16. Wingard JR. Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
17. 17. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37:1847-9.
18. 18. Persat F, Marzullo C, Guyotat D, Rochet MJ, Piens MA. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28:838-41.
19. 19. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32(Suppl 1):103-8.
20. 20. Prentice AG, Warnock DW, Johnson SAN, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247-52.
21. 21. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a double-blind, multicenter trial. Clin Infect Dis 1999; 28: 250-5.
22. 22. Gotzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997; 314:1238-44.